R.E. Aarnoutse

785 total citations
13 papers, 558 citations indexed

About

R.E. Aarnoutse is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, R.E. Aarnoutse has authored 13 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 5 papers in Virology and 4 papers in Molecular Biology. Recurrent topics in R.E. Aarnoutse's work include HIV/AIDS drug development and treatment (7 papers), Tuberculosis Research and Epidemiology (6 papers) and HIV Research and Treatment (5 papers). R.E. Aarnoutse is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), Tuberculosis Research and Epidemiology (6 papers) and HIV Research and Treatment (5 papers). R.E. Aarnoutse collaborates with scholars based in Netherlands, United Kingdom and Germany. R.E. Aarnoutse's co-authors include David M. Burger, Martin J. Boeree, C.P.W.G.M. Verwey-van Wissen, Stephen H. Gillespie, Georgette Plemper van Balen, Andreas H. Diacon, Jakko van Ingen, Rodney Dawson, P. R. Donald and Y. A. Hekster and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and European Respiratory Journal.

In The Last Decade

R.E. Aarnoutse

13 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R.E. Aarnoutse Netherlands	12	375	182	113	102	87	13	558
Ilaria Motta Italy	15	430 1.1×	264 1.5×	49 0.4×	107 1.0×	79 0.9×	31	605
A. K. Hemanth Kumar India	14	527 1.4×	341 1.9×	232 2.1×	99 1.0×	68 0.8×	31	757
Sandra Castel South Africa	11	343 0.9×	183 1.0×	113 1.0×	66 0.6×	58 0.7×	34	498
Lynn L. Estes United States	14	313 0.8×	205 1.1×	217 1.9×	85 0.8×	59 0.7×	36	703
Hanneke M. J. Nijland Netherlands	6	505 1.3×	368 2.0×	149 1.3×	173 1.7×	63 0.7×	7	660
Aurélie Barrail‐Tran France	16	387 1.0×	112 0.6×	39 0.3×	70 0.7×	75 0.9×	35	639
Melissa Engle United States	13	584 1.6×	408 2.2×	132 1.2×	163 1.6×	113 1.3×	19	786
Lillian Ting Canada	15	537 1.4×	273 1.5×	135 1.2×	96 0.9×	146 1.7×	26	1.1k
Rosa María López Spain	18	534 1.4×	326 1.8×	86 0.8×	126 1.2×	103 1.2×	44	888
Alfonso Domínguez‐Gil Spain	14	279 0.7×	114 0.6×	269 2.4×	34 0.3×	128 1.5×	26	863

Countries citing papers authored by R.E. Aarnoutse

Since Specialization

Citations

This map shows the geographic impact of R.E. Aarnoutse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.E. Aarnoutse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.E. Aarnoutse more than expected).

Fields of papers citing papers by R.E. Aarnoutse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.E. Aarnoutse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.E. Aarnoutse. The network helps show where R.E. Aarnoutse may publish in the future.

Co-authorship network of co-authors of R.E. Aarnoutse

This figure shows the co-authorship network connecting the top 25 collaborators of R.E. Aarnoutse. A scholar is included among the top collaborators of R.E. Aarnoutse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.E. Aarnoutse. R.E. Aarnoutse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Savić, Radojka M., Martin J. Boeree, Charles A. Peloquin, et al.. (2021). Optimising pyrazinamide for the treatment of tuberculosis. European Respiratory Journal. 58(1). 2002013–2002013. 23 indexed citations

Aarnoutse, R.E., Gibson Kibiki, Klaus Reither, et al.. (2017). Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy. 61(11). 56 indexed citations

Marais, Ben J., Suzaan Marais, Reinout van Crevel, et al.. (2016). Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies. Clinical Infectious Diseases. 64(4). 501–509. 52 indexed citations

Brake, Lindsey H. M. te, Rovina Ruslami, Fieke Mooren, et al.. (2015). Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 59(6). 3233–3239. 18 indexed citations

Pranger, Arianna D., Jan‐Willem C. Alffenaar, & R.E. Aarnoutse. (2011). Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach. Current Pharmaceutical Design. 17(27). 2900–2930. 23 indexed citations

Ingen, Jakko van, R.E. Aarnoutse, P. R. Donald, et al.. (2011). Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?. Clinical Infectious Diseases. 52(9). e194–e199. 178 indexed citations

Boogaard, Jossy van den, Hadija Semvua, Martin J. Boeree, R.E. Aarnoutse, & Gibson Kibiki. (2009). Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment. Journal of Antimicrobial Chemotherapy. 65(1). 145–147. 13 indexed citations

Droste, J. A. H., R.E. Aarnoutse, & D.M. Burger. (2007). Determination of Emtricitabine in Human Plasma using HPLC with Fluorometric Detection. Journal of Liquid Chromatography & Related Technologies. 30(18). 2769–2778. 24 indexed citations

Aarnoutse, R.E., Jan Kleinnijenhuis, Peter J. Koopmans, et al.. (2005). Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clinical Pharmacology & Therapeutics. 78(6). 664–674. 49 indexed citations

10.

Porte, Charles la, R.E. Aarnoutse, P.P. Koopmans, et al.. (2005). Pharmacokinetic Interaction Study of Indinavir/Ritonavir and the Enteric‐Coated Capsule Formulation of Didanosine in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(2). 211–218. 6 indexed citations

11.

Wissen, C.P.W.G.M. Verwey-van, R.E. Aarnoutse, & David M. Burger. (2004). Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. Journal of Chromatography B. 816(1-2). 121–129. 68 indexed citations

12.

Aarnoutse, R.E., J. A. H. Droste, Joep J. G. van Oosterhout, et al.. (2003). Pharmacokinetics, food intake requirements and tolerability of once‐daily combinations of nelfinavir and low‐dose ritonavir in healthy volunteers. British Journal of Clinical Pharmacology. 55(2). 115–125. 16 indexed citations

13.

Aarnoutse, R.E., C.P.W.G.M. Verwey-van Wissen, W.J.M. Underberg, et al.. (2001). High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. Journal of Chromatography B Biomedical Sciences and Applications. 764(1-2). 363–384. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact